| |
All patients
|
Neurological Symptoms
| |
|---|
| |
(n = 80)
|
Non-Severe (n = 70)
|
Severe (n = 10)
|
p-value*
|
|---|
|
Age (Years)
|
43.4 ± 2.0
|
45.2 ± 2.1
|
30.0 ± 3.5
|
0.00
|
|
Gender (% female)
|
38 (47.5)
|
32 (45.7)
|
4 (40)
|
0.39
|
|
Ethnicity:
| | | |
0.03
|
|
Arab
|
25 (31.3)
|
24 (34.3)
|
1 (10)
| |
|
Jews
|
54 (67.5)
|
46 (66.7)
|
8 (80)
| |
|
Others
|
1 (1.3)
|
0
|
1 (10)
| |
|
Smokers
|
6 (7.5)
|
6 (8.9)
|
0 (0)
|
0.196
|
|
Chronic Carbamazepine users
|
67 (83.8)
|
59 (84.3)
|
8 (80)
|
0.32
|
|
Indications for carbamazepine:
|
|
Epileptic seizures
|
50 (62.5)
|
47 (67.1)
|
4 (40)
|
0.09
|
|
Psychiatric disorder
|
27 (33.7)
|
20 (28.5)
|
7 (70)
|
0.013
|
|
Neuropathic pain
|
4 (5)
|
4 (5.7)
|
0 (0)
|
0.29
|
|
Othersa
|
5 (6.2)
|
5 (7.1)
|
0 (0)
| |
- *P-value was calculated by t-tests for continuous variables and Chi-square test for ordinal variables
- aOthers- primary sclerosis, psychomotor retardation and accidental ingestion
